

1 Original Research Article

2 Metallo- β -lactamase mediated rapid increase in carbapenem resistance of 3 *Pseudomonas aeruginosa*

4 List of Authors and Affiliations

5 Hasnain Anjum^{1*}, Shomaia Yasmin Mitu^{2*}, Md. Shamsul Arefin³, Meftahul Jannat
6 Mitu⁴, Md. Sabir Hossain⁵, Salequl Islam⁶, M.A. Karim Rumi⁷, M. Hasibur Rahman^{8#}

- 7 1. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
8 anjumabir27@gmail.com.
- 9 2. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
10 shomaiamitu@gmail.com.
- 11 3. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
12 arefin1120@gmail.com.
- 13 4. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh. Email:
14 mitumeftahul1@gmail.com.
- 15 5. Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka-1342,
16 Bangladesh. Email: sabirhossain@juniv.edu
- 17 6. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh; Email:
18 salequl@juniv.edu.
- 19 7. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas
20 City, KS 66160, USA; Email: mrumi@kumc.edu.
- 21 8. Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh; Email:
22 hasiburku@juniv.edu.

24 Corresponding Author:

25 M. Hasibur Rahman; Professor, Department of Microbiology, Jahangirnagar University, Savar, Dhaka-
26 1342, Bangladesh; Email: hasiburku@juniv.edu <https://orcid.org/0000-0001-7213-2158>

27 *Hasnain Anjum and Shomaia Yasmin Mitu contributed equally to this work. Author order was
28 determined in order of increasing seniority.;

29

30

31

32

33

34

35 **Metallo- β -lactamase mediated rapid increase in carbapenem resistance of** 36 ***Pseudomonas aeruginosa***

37 **Abstract:** Antibiotic-resistant *Pseudomonas aeruginosa* is a common nosocomial pathogen
38 all over the world. We detected the presence of *P. aeruginosa* in 22% (53 out of 238) of
39 the test samples collected from patients with infections including secondary wound
40 infections, abscesses and urinary tract infections admitted to two academic hospitals in
41 Bangladesh. Resistance to carbapenems (imipenem, and meropenem) was present
42 among 30% (16 out of 53) of these clinical *P. aeruginosa* isolates, which is more than 2-
43 fold higher compared to that of previous studies. Such a rapid increase in carbapenem
44 resistance was mediated by metallo- β -lactamase (MBL). Expression of MBL was
45 detected in 90% (14 out of 16) of these resistant isolates. Molecular analyses revealed
46 that the carbapenem-resistant isolates carried at least one of the MBL variants, either
47 *bla*-VIM or *bla*-NDM-1. All the *bla*-NDM-1 positives carried a 0.5 MDa plasmid. ERIC-
48 PCR revealed the highly heterogeneous nature of the *P. aeruginosa* isolates indicating
49 multiple sources of infection within the hospital. However, the majority of XDR isolates
50 belonged to a single cluster of drug-resistant bacterial infections. These findings
51 indicate that Metallo- β -lactamase (MBL) mediated resistance to carbapenem in *P.*
52 *aeruginosa* poses a serious threat to the spread of infections among hospitalized patients.

53 **Keywords:** *Pseudomonas aeruginosa*; nosocomial infection; carbapenem-resistance,
54 metallo- β -lactamase; genetic variants.

55 56 **1. Introduction**

57 *Pseudomonas aeruginosa* (*P. aeruginosa*) is one of the most common pathogens
58 associated with nosocomial infections (1). This Gram-negative bacterium is a member of
59 the infamous ESKAPE group of bacteria, known for their rapidly increasing antibiotic
60 resistance in healthcare facilities (2, 3). The global priority list of emerging antibiotic-
61 resistant bacteria recognizes *P. aeruginosa* as a critical pathogen that requires an in-
62 depth study(4). It is commonly associated with wound infections, urinary tract
63 infections (UTIs) (particularly catheter-associated UTIs), ventilator-associated
64 respiratory tract infections (RTI), and cystic fibrosis (1, 5).

65 The carbapenem group of antibiotics (imipenem, meropenem, ertrapenem, and
66 doripenem) is clinically effective against *P. aeruginosa* (5, 6). However, a steep rise in
67 carbapenem resistance has been reported over the last few years (7). Susceptibility to
68 carbapenems is dependent on their entry to bacteria through the outer membrane porin
69 protein OprD (8). Thus, a reduced expression of OprD can lead to carbapenem
70 resistance in *P. aeruginosa* (8). Other mechanisms of carbapenem resistance include
71 decreased permeability of outer membrane porins, increased production of molecular

72 efflux pumps, acquisition of chromosomal cephalosporinases, and expression of broad-
73 spectrum beta-lactamases, especially carbapenemases like metallo- β -lactamases
74 (MBLs)(9). Acquisition of MBLs through horizontal gene transfer has been increasingly
75 identified in Gram-negative isolates from hospitalized patients(10). These enzymes can
76 hydrolyze most of the β -lactams and are not repressed by serine β -lactamase repressors
77 like tazobactam and clavulanates (11). As MBLs depend on bivalent zinc ions for the
78 hydrolysis of β -lactam antibiotics, they are inactivated by metal chelators like
79 EDTA(12).

80 The origins of MBLs remain unclear; it is most likely transferred from
81 environmental bacteria like *Enterobacteriaceae* (13). The genes encoding MBLs are mainly
82 spread through mobile genetic elements like integrons residing on plasmids or bacterial
83 genomic DNA (13, 14). The majority of the MBLs belong to subclass B1 (15, 16) and the 3
84 most common MBLs, namely IMP (imipenemase), VIM (Verona integron-encoded
85 metallo- β -lactamase), and NDM(New Delhi metallo- β -lactamase) are well-known for
86 their epidemiological and clinical importance (12, 13, 17). The *bla*-VIM was first detected
87 in *P. aeruginosa* in European countries during the late 1990s, and more than 20 different
88 VIM allotypes have been identified worldwide (13, 18). However, *bla*-NDM-1, which
89 was detected in *K. pneumoniae* in 2008, has been widely disseminated among
90 *Enterobacteriaceae* in India (14). A significant increase in the prevalence of these MBLs
91 has been seen throughout the world, including the United Kingdom and Southeast-
92 Asian countries like India, Pakistan, and Bangladesh (14, 19, 20).

93 In this study, we investigated the presence of drug-resistant *P. aeruginosa* infection
94 among hospitalized patients in Dhaka, Bangladesh. We observed that resistance to
95 carbapenems has doubled in the past decade (6). Such a rapid increase in carbapenem
96 resistance was mediated by metallo- β -lactamase (MBL). We detected the expression of
97 MBL-variants in carbapenem resistant *P. aeruginosa* isolates and determined the
98 heterogenic nature of the clinical isolates.

99

100 2. Materials and Methods

101 2.1 Isolation and Characterization of clinical isolates

102 Clinical samples were collected from patients admitted to two academic hospitals,
103 Enam Medical College Hospital (EMCH) and Gonoshasthaya Samaj Vittik Medical
104 College Hospital (GMCH) located at Savar, Bangladesh. The presence of *P. aeruginosa*
105 was studied in 238 samples consisting of 115 midstream urine, 69 pus, 21 secondary
106 wound infection swab, 12 urinary catheter swab, 10 burn wounds, 9 blood, and 2
107 tracheal aspirate specimens. *Pseudomonas* Cetrinide Agar (Scharlab S. L., Spain) was
108 used to determine the colony morphology, fluorescence, and pigment production,
109 followed by conventional biochemical tests according to Bargey's Manual of Systemic
110 Bacteriology for presumptive identification of *P. aeruginosa* as described previously (41,
111 42). Selected isolates were stored in glycerol broth at -80 °C.

112

113 2.2 Molecular Identification

114 Molecular identification was carried out by sequencing 16S rDNA of fourteen
115 representative isolates. DNA templates prepared from the selected isolates were
116 subjected to polymerase chain reaction (PCR) (43). The PCR products were purified
117 using Promega Wizard SV Gel and PCR Clean-up System, USA and sequenced. The
118 identity of the isolates was confirmed by BLAST analysis.

119

120 2.3. Screening of Carbapenem Resistance

121 To determine the susceptibility of clinical *P. aeruginosa* isolates to carbapenem
122 antibiotics, Kirby Bauer disc diffusion test was used (44), followed by determination of
123 MIC against Imipenem (IMP 10 µg) and Meropenem (MPM 10 µg). Antibiotic discs
124 were obtained from Oxoid, UK. *P. aeruginosa* PAO1 was used as control. Results were
125 interpreted according to CLSI standards and guidelines [24]. MDR nature of isolates
126 was observed against nine additional antibiotics of six different groups (data not
127 included in this study) and interpreted accordingly (45, 46).

128

129 2.4. Phenotypic Detection of MBL Production

130 To detect the production of MBL, imipenem-resistant isolates were subjected to
131 IMP-EDTA double disc synergistic test. The pure cultures of selected isolates were
132 plated on Mueller-Hinton agar (Oxoid, UK) to prepare bacterial lawn. Two imipenem
133 (IMP 10 µg) disks were placed on prepared lawn by at least 20 mm distance. One of the
134 disks was impregnated with 0.5M EDTA to achieve 750 µg/disk concentrations, which
135 can act on MBL by removing zinc ions from the active site of the enzyme, effectively
136 nullifying its activity. The plates were incubated overnight at 37 °C, and zone diameters
137 for both IMP and IMP-EDTA disks were measured. Isolates exhibiting ≥17 mm
138 inhibition zones with IMP-EDTA disc were considered MBL-positive, while isolates
139 with ≤14 mm inhibition zones were considered MBL-negative (47).

140

141 2.5. PCR Detection of MBL

142 The presence of genes encoding four different variants of MBLs *bla*-NDM-1, *bla*-
143 SPM, *bla*-IMP, and *bla*-VIM were investigated in all isolates exhibiting phenotypic
144 resistance against imipenem. PCR reagents were obtained from Promega, USA and the
145 primers were designed according to previous publications (24, 48). The primer as well
146 as annealing temperatures are listed in **Table 1**. For each PCR reaction, 2 µl of prepared
147 bacterial DNA was added to 16 µl of prepared PCR-ready mix containing (1X PCR
148 buffer, 2.5mM MgCl₂, 0.25 mM dNTP, 1IU of Taq DNA polymerase, 10 pmol of each
149 primer), and deionized water was added to obtain a final volume of 25 µl. The PCR
150 reactions were carried out as indicated in **Table 3**. The PCR products were visualized
151 using a UV transilluminator after electrophoresis in 1% agarose gel.

152

153 2.6. ERIC-PCR for Species Diversity Analysis

154 To observe the diversity among the *P. aeruginosa* isolates, ERIC-PCR
155 (Enterobacterial Repetitive Intergenic Consensus- Polymerase Chain Reaction) was
156 performed using the primer sequence mentioned elsewhere (49). PCR products were
157 separated on 2% agarose gel and visualized under a UV transilluminator. The cluster
158 analysis was conducted by using DendroUPGMA (21, 50).

159

160 2.7. Plasmid Extraction

161 Plasmids from carbapenem-resistant *P. aeruginosa* isolates were extracted according
162 to the modified hot alkaline lysis method by Kado and Liu (51). Extracted plasmids
163 were electrophoresed in 0.7% agarose gel with ethidium bromide (0.5 mg/mL) and
164 visualized under a UV transilluminator. Reference strains of *E. coli* K-12 V517 and PDK9
165 were used as control strains for the extraction method and plasmid size marker (52, 53).

166

167 2.8. Statistical Analysis

168 A validated questionnaire was used for data collection. Collected data were verified
169 and analyzed by using IBM SPSS Statistics Data Editor (Version 21) and STATA 15.

170

171 3. Results

172 3.1. Isolation and identification of *P. aeruginosa*

173 A total of 238 clinical samples were collected from the patients admitted into two
174 academic hospitals in Savar City, at the outskirts of Dhaka, the capital of Bangladesh.
175 Most of clinical samples were collected from patients with UTI, followed by secondary
176 wound infections and abscesses (**Table 1**). The samples were tested for the presence of
177 *P. aeruginosa* and 53 (~22%) showed growth on selective ceftrimide agar, which were
178 further characterized through standard biochemical tests. Identification of the clinical
179 isolates was confirmed by PCR-based 16SrDNA sequence analyses, which showed a 95
180 to 99% identity to *P. aeruginosa* sequence (e-value ≤ 0). We detected that wound
181 infections were more frequently positive for *P. aeruginosa* compared to other infections.

182

183 3.2. Carbapenem resistance in clinical *P. aeruginosa* isolates

184 All 53 isolates of *P. aeruginosa* were tested for susceptibility to carbapenem
185 (imipenem and meropenem) using a disk-diffusion method followed by minimum
186 inhibitory concentration (MIC) assays. Out of 53 isolates, 16 (30%) were resistant to both
187 imipenem and meropenem. However, the antibiotic tolerance levels varied widely in
188 the MIC assay. While 50% (8/16) of carbapenem-resistant isolates showed a moderate
189 resistance (8 $\mu\text{g/ml}$), the other 50% isolates had a much higher resistance level (≥ 16
190 to 128 $\mu\text{g/ml}$). Among the 16 carbapenem-resistant *P. aeruginosa* isolates, 6 were from
191 GMCH (38%), while the rest 10 (62%) were from the EMCH (**Table 1**). Antibiogram
192 profile identified 12 isolates as multidrug resistant (MDR), and another 2 isolates as

193 extensively drug resistant (XDR). Moreover, uniform resistance against third generation
194 cephalosporins like ceftriaxone and cefotaxime and significantly lower susceptibility to
195 important antibiotics like azithromycin and tetracycline was observed, which is
196 alarmingly higher than previous regional reports.

197

198 3.3. Detection of MBL in *P. aeruginosa* isolates

199 All of the 16 imipenem-resistant *P. aeruginosa* isolates were subjected to enzymatic
200 activity and PCR based genotypic detection of MBL variants. Of the 16 isolates, 14
201 (~88%) were positive for MBL activity in an imipenem-EDTA double-disk synergistic
202 test. PCR-based detection of the MBL variants, *bla*-VIM, *bla*-NDM1, *bla*-IMP, and *bla*-
203 SPM, showed that 10 out of the 16 (~63%) resistant isolates carried at least one. While
204 *bla*-VIM was detected in 7 out of 16 isolates (44%), *bla*-NDM-1 was detected in 3 isolates
205 (19.75%) (**Figure 1**). We did not detect any of MBL variants, *bla*-VIM, *bla*-NDM1, *bla*-
206 IMP, and *bla*-SPM in other 6 isolates. Moreover, none of the isolates were multiple MBL
207 genes carrier (**Table 3**).

208

209 3.4. Detection of plasmids in MBL positive isolates

210 Plasmid extraction and gel electrophoresis detected the presence of plasmids in 7
211 out of the 16 (43%) MBL-positive isolates. Among 7 *bla*-VIM positive isolates, 4 carried a
212 plasmid of 1.2 MDa, while the other 3 isolates did not carry any plasmid. In contrast all
213 3 of the *bla*-NDM1 positive *P. aeruginosa* isolates carried a plasmid of 0.5 MDa (**Table 3**).

214

215 3.5. ERIC-PCR and cluster analysis

216 Enterobacterial Repetitive Intergenic Consensus- Polymerase Chain Reaction
217 (ERIC-PCR) was performed to determine the possible epidemiological relationships
218 among the clinical *P. aeruginosa* isolates (21). Our results revealed distinct patterns of
219 DNA, indicating species diversity among carbapenem-resistant *P. aeruginosa* isolates.
220 Highly heterogeneous results indicated that the isolates did not share significant genetic
221 relatedness. Phylogenetic cluster analysis based on unweighted pair group method with
222 arithmetic mean (UPGMA) exhibited the presence of three distinct clusters I-III (**Figure**
223 **2**). The majority of the XDR isolates belonged to cluster III, while cluster I and II were
224 composed of MDR isolates.

225

226 4. Discussion

227 Rapid development of antibiotic-resistance in Gram-negative bacteria including *P.*
228 *aeruginosa* has become a major public health concern all over the world (2, 3). There is an
229 alarming increase in MDR, XDR, and PDR isolates of *P. aeruginosa* (22, 23). In this study,
230 we also observed frequent occurrences of MDR among the *P. aeruginosa* isolates in
231 Bangladesh. Remarkably, one in every three isolates was resistant to carbapenems.

232 While the interquartile range (IQR) of imipenem resistance found in a systematic review
233 covering studies during 2004 to 2018 was 13.5%, we detected a huge increase to 30%(6).

234 Our results indicate that the rapid increase in imipenem resistance among *P.*
235 *aeruginosa* clinical isolates in Bangladesh is mediated by MBLs. About 88% of the
236 resistant isolates were positive for MBL production. The MBL-positive isolates also
237 showed an elevated level of MIC values of imipenem and meropenem. Resistance to
238 carbapenems is often associated with the acquisition and expression of the MBLs, which
239 includes *bla*-IMP, *bla*-VIM, *bla*-GIM, *bla*-SPM, *bla*-NDM and *bla*-SIM genes (24). In this
240 study 71% of the carbapenem-resistant isolates were found to carry variants of MBL
241 genes. While the majority (7/16; 44%) of the isolates carried *bla*-VIM, only 19% (3/16)
242 carried *bla*-NDM-1. The current investigation shows a much higher prevalence of MBL
243 genes among *P. aeruginosa* isolates compared to similar studies conducted in India
244 (12%), Pakistan (18%), China (55%), Iran (40%), and Nigeria (17%)(25-28). Moreover, it
245 needs to be noted that we investigated the presence of only four variants (*bla*-IMP, *bla*-
246 VIM, *bla*-SPM, and *bla*-NDM-1). Therefore, we cannot exclude the presence of other
247 MBL variants in remaining 29% of the isolates.

248 In this study, *bla*-VIM variant was found to be the most prevalent among the MBL
249 genes tested (7/16, 44%). Dissemination of novel variants of *bla*-VIM is commonly
250 mediated by class I integrons like *In58* and *In59* gene cassettes (29, 30). Plasmids
251 carrying class I integrons possess strong dissemination potential (31, 32). However,
252 several of the *bla*-VIM carrier isolates (3/7, 42%) in our study did not carry any plasmid,
253 implying that these isolates may have integrons in their chromosomal DNA.

254 In this study, the presence of *bla*-NDM-1 was detected among 3 of 16 carbapenem-
255 resistant isolates. Classically *bla*-NDM-1 encoding gene is also plasmid-borne, which
256 has been found to be disseminated through the members of the *Enterobacteriaceae* and
257 *Pseudomonaceae* family (32, 33). Transmission of *bla*-NDM-1 has been also reported in
258 *Acinetobacter baumannii* by transposon Tn125 (34, 35). It has been shown that *bla*-NDM-1
259 gene can be carried on plasmids of diverse sizes with incompatibility types that allow
260 interspecies, intergenus, and interfamily transfer (36). In this study, we observed the
261 presence of a 0.5 MDa plasmid in *P. aeruginosa* isolates that carried the *bla*-NDM-1 gene.
262 Remarkably, all *bla*-NDM-1 carriers were isolated from UTI and catheter-associated
263 infections.

264 We employed ERIC-PCR for molecular typing of genetic relatedness among the *P.*
265 *aeruginosa* isolates. ERIC-PCR revealed that the carbapenem-resistant *P. aeruginosa*
266 isolates were distributed in three distinct clusters, with the majority belonging to cluster
267 III. Overall analyses of our ERIC-PCR data indicated a heterogeneous nature of *P.*
268 *aeruginosa* isolates and possible independent sources of dissemination. Several previous
269 studies also reported similar heterogenous nature of *P. aeruginosa* isolates (26, 37).
270 However, the XDR isolates found in this study were all grouped in cluster III in ERIC-
271 PCR analyses.

272 Our test samples were collected from two academic hospitals. Interestingly, both
273 carbapenem resistance and the presence of MBL pattern was different between the two
274 hospitals. Although 35% (6/17) of the *P. aeruginosa* from GMCH were carbapenem
275 resistant, 2 were phenotypically MBL negative and none were positive for the presence
276 of MBL variants tested. In contrast, 28% (10/36) of the *P. aeruginosa* from EMCH were
277 carbapenem resistant, but all the isolates carried MBL genes. Compared to GMCH,
278 EMCH is a larger, tertiary care hospital that admits more patients for a longer period,
279 which might establish a favorable niche for dissemination of MBL genes among
280 nosocomial agents like *P. aeruginosa*. Previous studies also suggested that larger number
281 of patients may harbor frequent source of drug resistant bacterial infections and
282 prolonged hospitalization may increase the risk of acquisition of drug resistance
283 elements through horizontal gene transfer (38, 39). A recent study in Bangladesh also
284 demonstrated that hospital environment is a major reservoir for carbapenem-resistant
285 *P. aeruginosa* with MBL carriage (40).

286 Indiscriminate use of therapeutically important antibiotics is presumed to be the
287 major cause of antibiotic resistance and the transmission of such resistant pathogens is
288 more likely among hospitalized patients, especially those who need prolonged stay.
289 Horizontal transfer of antibiotic resistance determinants further complicates the control
290 strategies. Our results suggest that rapid screening by molecular techniques like ERIC-
291 PCR may help track multidrug-resistant *P. aeruginosa* outbreaks in hospitals and
292 develop point-of-care surveillance.

293

294 **5. Conclusions**

295 The emerging threat of ever-increasing antibiotic resistance among *P. aeruginosa* of
296 clinical origin is a major concern for the treatment of nosocomial infections caused by
297 the pathogen. The magnitude of multidrug resistance and the presence of MBL variants
298 in clinical settings reported in this study require immediate attention to improve
299 infection control and prevention programs. This study also suspects the hospital
300 environment to facilitate the horizontal transfer of resistance elements like MBL genes.
301 Implementation of antibiotic stewardship policy alongside proper infection control now
302 has become a public health emergency to combat the emerging threat of superbugs in
303 healthcare settings of developing countries like Bangladesh.

304

305 **6. Ethics statement**

306

307 This study was approved by the Ethics and Research Review Committee of the
308 Jahangirnagar University Faculty of Biological Sciences [Ref No: BBEC, JU/M 2020 (1)4].
309 Written informed consent was obtained from patients for sample collection, and their
310 personal identities along with other information were anonymized.

311 **Author Contributions:** All authors made a significant contribution to the work
312 reported. M.H.R. conceptualized and supervised the study. H.A., S.Y.M., M.S.A, and
313 M.J.M. collected the clinical samples and conducted laboratory experiments. H.A. and
314 S.Y.M. also analyzed the data and prepared the manuscript. M.S.H. and S.I. made
315 significant contributions to the study design and M.A.K.R. edited the manuscript. The
316 authors agree and approve the content of the final version of the manuscript.

317 **Funding:** M. H.R. received funding support from the Grants for Advanced Research in
318 Education (GARE), the Ministry of Education, Bangladesh (Award ID: bs-
319 37.20.0000.004.033.020.2016.673).

320 **Acknowledgments:** The authors would like to thank the laboratory personnel of Enam
321 Medical College Hospital and Gonoshasthaya Medical College Hospital, Dhaka,
322 Bangladesh, for their support in the collection of the clinical samples.

323 **Conflicts of Interest:** The authors declare that they have no conflict of interest.
324

325 References

- 326
327 1. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-
328 associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest*. 2005;128(6):3854-62.
329 doi: 10.1378/chest.128.6.3854. PubMed PMID: 16354854.
- 330 2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE!
331 An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48(1):1-12. doi: 10.1086/595011.
332 PubMed PMID: 19035777.
- 333 3. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. *Infect Control Hosp*
334 *Epidemiol*. 2010;31 Suppl 1:S7-10. doi: 10.1086/655995. PubMed PMID: 20929376.
- 335 4. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens.
336 *Pathogens*. 2021;10(10). Epub 20211012. doi: 10.3390/pathogens10101310. PubMed PMID: 34684258; PubMed Central
337 PMCID: PMC8541462.
- 338 5. Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by *Pseudomonas*
339 *aeruginosa*: a minireview. *J Infect Public Health*. 2009;2(3):101-11. Epub 20090919. doi: 10.1016/j.jiph.2009.08.003.
340 PubMed PMID: 20701869.
- 341 6. Ahmed I, Rabbi MB, Sultana S. Antibiotic resistance in Bangladesh: A systematic review. *Int J Infect Dis*.
342 2019;80:54-61. Epub 20190110. doi: 10.1016/j.ijid.2018.12.017. PubMed PMID: 30634043.
- 343 7. Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, et al. All-cause mortality rates in adults with
344 carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective,
345 randomized, interventional clinical studies. *Expert Rev Anti Infect Ther*. 2022;20(5):707-19. Epub 20220112. doi:
346 10.1080/14787210.2022.2020099. PubMed PMID: 34937518.
- 347 8. Beig M, Taheri M, Arabestani MR. Expression of MexAB-OprM efflux pump and OprD porin in
348 carbapenemase producing *Pseudomonas aeruginosa* clinical isolates. *Gene Reports*. 2020;20:100744. doi:
349 <https://doi.org/10.1016/j.genrep.2020.100744>.
- 350 9. Rostami S, Farajzadeh Sheikh A, Shoja S, Farahani A, Tabatabaiefar MA, Jolodar A, et al. Investigating of
351 four main carbapenem-resistance mechanisms in high-level carbapenem resistant *Pseudomonas aeruginosa* isolated
352 from burn patients. *J Chin Med Assoc*. 2018;81(2):127-32. Epub 20171009. doi: 10.1016/j.jcma.2017.08.016. PubMed
353 PMID: 29033110.

- 354 10. Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB, Patwardhan NS. Metallo- β -lactamase-producing clinical
355 isolates from patients of a tertiary care hospital. *J Lab Physicians*. 2011;3(2):93-7. doi: 10.4103/0974-2727.86841.
356 PubMed PMID: 22219562; PubMed Central PMCID: PMC3249725.
- 357 11. Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, et al. Aztreonam plus Clavulanate,
358 Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo- β -Lactamase-Producing Gram-Negative
359 Bacteria. *Antimicrob Agents Chemother*. 2019;63(5). Epub 20190425. doi: 10.1128/aac.00010-19. PubMed PMID:
360 30858212; PubMed Central PMCID: PMC6496057.
- 361 12. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? *Clin*
362 *Microbiol Rev*. 2005;18(2):306-25. doi: 10.1128/cmr.18.2.306-325.2005. PubMed PMID: 15831827; PubMed Central
363 PMCID: PMC1082798.
- 364 13. Cornaglia G, Giamarellou H, Rossolini GM. Metallo- β -lactamases: a last frontier for β -lactams? *Lancet Infect*
365 *Dis*. 2011;11(5):381-93. doi: 10.1016/s1473-3099(11)70056-1. PubMed PMID: 21530894.
- 366 14. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new
367 antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.
368 *Lancet Infect Dis*. 2010;10(9):597-602. Epub 20100810. doi: 10.1016/s1473-3099(10)70143-2. PubMed PMID: 20705517;
369 PubMed Central PMCID: PMC2933358.
- 370 15. Bush K. The ABCD's of β -lactamase nomenclature. *J Infect Chemother*. 2013;19(4):549-59. Epub 20130705.
371 doi: 10.1007/s10156-013-0640-7. PubMed PMID: 23828655.
- 372 16. Mojica MF, Bonomo RA, Fast W. B1-Metallo- β -Lactamases: Where Do We Stand? *Curr Drug Targets*.
373 2016;17(9):1029-50. doi: 10.2174/1389450116666151001105622. PubMed PMID: 26424398; PubMed Central PMCID:
374 PMC4814356.
- 375 17. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev*. 2007;20(3):440-58,
376 table of contents. doi: 10.1128/cmr.00001-07. PubMed PMID: 17630334; PubMed Central PMCID: PMC1932750.
- 377 18. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, et al. Cloning and
378 characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa*
379 clinical isolate. *Antimicrob Agents Chemother*. 1999;43(7):1584-90. doi: 10.1128/aac.43.7.1584. PubMed PMID:
380 10390207; PubMed Central PMCID: PMC89328.
- 381 19. Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo- β -
382 lactamase (NDM): a threat to public health. *BMC Microbiol*. 2017;17(1):101. Epub 20170427. doi: 10.1186/s12866-017-
383 1012-8. PubMed PMID: 28449650; PubMed Central PMCID: PMC5408368.
- 384 20. Urmi UL, Nahar S, Rana M, Sultana F, Jahan N, Hossain B, et al. Genotypic to Phenotypic Resistance
385 Discrepancies Identified Involving β -Lactamase Genes, blaKPC, blaIMP, blaNDM-1, and blaVIM in Uropathogenic
386 *Klebsiella pneumoniae*. *Infect Drug Resist*. 2020;13:2863-75. Epub 20200818. doi: 10.2147/idr.S262493. PubMed PMID:
387 32903880; PubMed Central PMCID: PMC7445497.
- 388 21. Ranjbar R, Tabatabaee A, Behzadi P, Kheiri R. Enterobacterial Repetitive Intergenic Consensus Polymerase
389 Chain Reaction (ERIC-PCR) Genotyping of *Escherichia coli* Strains Isolated from Different Animal Stool Specimens.
390 *Iran J Pathol*. 2017;12(1):25-34. Epub 20161229. PubMed PMID: 29760750; PubMed Central PMCID: PMC5938721.
- 391 22. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, et al. An international multicenter
392 retrospective study of *Pseudomonas aeruginosa* nosocomial pneumonia: impact of multidrug resistance. *Crit Care*.
393 2015;19(1):219. Epub 20150506. doi: 10.1186/s13054-015-0926-5. PubMed PMID: 25944081; PubMed Central PMCID:
394 PMC4446947.
- 395 23. Palavutitotai N, Jitmuang A, Tongchai S, Kiratisin P, Angkasekwinai N. Epidemiology and risk factors of
396 extensively drug-resistant *Pseudomonas aeruginosa* infections. *PLoS One*. 2018;13(2):e0193431. Epub 20180222. doi:
397 10.1371/journal.pone.0193431. PubMed PMID: 29470531; PubMed Central PMCID: PMC5823452.
- 398 24. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding
399 acquired metallo-beta-lactamases. *J Antimicrob Chemother*. 2007;59(2):321-2. Epub 20061221. doi: 10.1093/jac/dkl481.
400 PubMed PMID: 17185300.
- 401 25. Mohanam L, Menon T. Coexistence of metallo-beta-lactamase-encoding genes in *Pseudomonas aeruginosa*.
402 *Indian J Med Res*. 2017;146(Supplement):S46-s52. doi: 10.4103/ijmr.IJMR_29_16. PubMed PMID: 29205195; PubMed
403 Central PMCID: PMC5735570.
- 404 26. Saleem S, Bokhari H. Resistance profile of genetically distinct clinical *Pseudomonas aeruginosa* isolates from
405 public hospitals in central Pakistan. *J Infect Public Health*. 2020;13(4):598-605. Epub 20190926. doi:
406 10.1016/j.jiph.2019.08.019. PubMed PMID: 31564530.

- 407 27. Olaniran OB, Adeleke OE, Donia A, Shahid R, Bokhari H. Incidence and Molecular Characterization of
408 Carbapenemase Genes in Association with Multidrug-Resistant Clinical Isolates of *Pseudomonas aeruginosa* from
409 Tertiary Healthcare Facilities in Southwest Nigeria. *Curr Microbiol.* 2021;79(1):27. Epub 20211214. doi:
410 10.1007/s00284-021-02706-3. PubMed PMID: 34905085.
- 411 28. Namaei MH, Yousefi M, Askari P, Roshanravan B, Hashemi A, Rezaei Y. High prevalence of multidrug-
412 resistant non-fermentative Gram-negative bacilli harboring bla (IMP-1) and bla (VIM-1) metallo-beta-lactamase genes
413 in Birjand, south-east Iran. *Iran J Microbiol.* 2021;13(4):470-9. doi: 10.18502/ijm.v13i4.6971. PubMed PMID: 34557275;
414 PubMed Central PMCID: PMC8421574.
- 415 29. Botelho J, Grosso F, Quinteira S, Brilhante M, Ramos H, Peixe L. Two decades of blaVIM-2-producing
416 *Pseudomonas aeruginosa* dissemination: an interplay between mobile genetic elements and successful clones. *J*
417 *Antimicrob Chemother.* 2018;73(4):873-82. doi: 10.1093/jac/dkx517. PubMed PMID: 29373674.
- 418 30. Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D. Molecular epidemiology of outbreak-related
419 *pseudomonas aeruginosa* strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene. *Antimicrob*
420 *Agents Chemother.* 2009;53(4):1325-30. Epub 20090121. doi: 10.1128/aac.01230-08. PubMed PMID: 19164147; PubMed
421 Central PMCID: PMC2663106.
- 422 31. Lombardi G, Luzzaro F, Docquier JD, Riccio ML, Perilli M, Coli A, et al. Nosocomial infections caused by
423 multidrug-resistant isolates of *pseudomonas putida* producing VIM-1 metallo-beta-lactamase. *J Clin Microbiol.*
424 2002;40(11):4051-5. doi: 10.1128/jcm.40.11.4051-4055.2002. PubMed PMID: 12409373; PubMed Central PMCID:
425 PMC139695.
- 426 32. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenem-
427 hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a *Pseudomonas aeruginosa*
428 clinical isolate in France. *Antimicrob Agents Chemother.* 2000;44(4):891-7. doi: 10.1128/aac.44.4.891-897.2000. PubMed
429 PMID: 10722487; PubMed Central PMCID: PMC89788.
- 430 33. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New
431 Delhi environment and its implications for human health: an environmental point prevalence study. *Lancet Infect*
432 *Dis.* 2011;11(5):355-62. Epub 20110407. doi: 10.1016/s1473-3099(11)70059-7. PubMed PMID: 21478057.
- 433 34. Pfeifer Y, Wilharm G, Zander E, Wichelhaus TA, Göttig S, Hunfeld KP, et al. Molecular characterization of
434 blaNDM-1 in an *Acinetobacter baumannii* strain isolated in Germany in 2007. *J Antimicrob Chemother.*
435 2011;66(9):1998-2001. Epub 20110621. doi: 10.1093/jac/dkr256. PubMed PMID: 21693460.
- 436 35. Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M, Nordmann P. Tn125-related acquisition of
437 blaNDM-like genes in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2012;56(2):1087-9. Epub 20111205.
438 doi: 10.1128/aac.05620-11. PubMed PMID: 22143526; PubMed Central PMCID: PMC3264265.
- 439 36. Carattoli A. Plasmids and the spread of resistance. *Int J Med Microbiol.* 2013;303(6-7):298-304. Epub
440 20130314. doi: 10.1016/j.ijmm.2013.02.001. PubMed PMID: 23499304.
- 441 37. Hematzadeh A, Haghkhah M. Biotyping of isolates of *Pseudomonas aeruginosa* isolated from human
442 infections by RAPD and ERIC-PCR. *Heliyon.* 2021;7(9):e07967. Epub 20210908. doi: 10.1016/j.heliyon.2021.e07967.
443 PubMed PMID: 34604557; PubMed Central PMCID: PMC8473555.
- 444 38. Stanton RA, Campbell D, McAllister GA, Breaker E, Adamczyk M, Daniels JB, et al. Whole-Genome
445 Sequencing Reveals Diversity of Carbapenem-Resistant *Pseudomonas aeruginosa* Collected through CDC's
446 Emerging Infections Program, United States, 2016-2018. *Antimicrob Agents Chemother.* 2022;66(9):e0049622. Epub
447 20220906. doi: 10.1128/aac.00496-22. PubMed PMID: 36066241; PubMed Central PMCID: PMC9487505.
- 448 39. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a
449 rundown of a global crisis. *Infect Drug Resist.* 2018;11:1645-58. Epub 20181010. doi: 10.2147/idr.S173867. PubMed
450 PMID: 30349322; PubMed Central PMCID: PMC6188119.
- 451 40. Saha K, Kabir ND, Islam MR, Amin MB, Hoque KI, Halder K, et al. Isolation and characterisation of
452 carbapenem-resistant *Pseudomonas aeruginosa* from hospital environments in tertiary care hospitals in Dhaka,
453 Bangladesh. *J Glob Antimicrob Resist.* 2022;30:31-7. Epub 20220418. doi: 10.1016/j.jgar.2022.04.008. PubMed PMID:
454 35447383.
- 455 41. Gilardi GL. Characterization of *Pseudomonas* species isolated from clinical specimens. *Appl Microbiol.*
456 1971;21(3):414-9. doi: 10.1128/am.21.3.414-419.1971. PubMed PMID: 4928600; PubMed Central PMCID: PMC377195.
- 457 42. O'Hara C M. Manual and automated instrumentation for identification of Enterobacteriaceae and other
458 aerobic gram-negative bacilli. *Clin Microbiol Rev.* 2005;18(1):147-62. doi: 10.1128/cmr.18.1.147-162.2005. PubMed
459 PMID: 15653824; PubMed Central PMCID: PMC544179.

- 460 43. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J
461 Bacteriol. 1991;173(2):697-703. doi: 10.1128/jb.173.2.697-703.1991. PubMed PMID: 1987160; PubMed Central PMCID:
462 PMC207061.
- 463 44. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk
464 method. Am J Clin Pathol. 1966;45(4):493-6. PubMed PMID: 5325707.
- 465 45. Gill MM, Usman J, Kaleem F, Hassan A, Khalid A, Anjum R, et al. Frequency and antibiogram of multi-drug
466 resistant *Pseudomonas aeruginosa*. J Coll Physicians Surg Pak. 2011;21(9):531-4. PubMed PMID: 21914408.
- 467 46. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant,
468 extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard
469 definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. Epub 20110727. doi: 10.1111/j.1469-
470 0691.2011.03570.x. PubMed PMID: 21793988.
- 471 47. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation
472 of metallo-beta-lactamase-producing clinical isolates of *Pseudomonas* spp. and *Acinetobacter* spp. J Clin Microbiol.
473 2002;40(10):3798-801. doi: 10.1128/jcm.40.10.3798-3801.2002. PubMed PMID: 12354884; PubMed Central PMCID:
474 PMC130862.
- 475 48. Rad ZR, Rad ZR, Goudarzi H, Goudarzi M, Alizade H, Hematian A, et al. Detection of New Delhi Metallo-
476 β -lactamase-1 among *Pseudomonas aeruginosa* isolated from adult and Pediatric patients in Iranian hospitals. Gene
477 Reports. 2021;23:101152. doi: <https://doi.org/10.1016/j.genrep.2021.101152>.
- 478 49. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to
479 fingerprinting of bacterial genomes. Nucleic Acids Res. 1991;19(24):6823-31. doi: 10.1093/nar/19.24.6823. PubMed
480 PMID: 1762913; PubMed Central PMCID: PMC329316.
- 481 50. Aljindan R, Alsamman K, Elhadi N. ERIC-PCR Genotyping of *Acinetobacter baumannii* Isolated from
482 Different Clinical Specimens. Saudi J Med Med Sci. 2018;6(1):13-7. Epub 20171214. doi: 10.4103/sjmms.sjmms_138_16.
483 PubMed PMID: 30787810; PubMed Central PMCID: PMC6196677.
- 484 51. Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol.
485 1981;145(3):1365-73. doi: 10.1128/jb.145.3.1365-1373.1981. PubMed PMID: 7009583; PubMed Central PMCID:
486 PMC217141.
- 487 52. Macrina FL, Kopecko DJ, Jones KR, Ayers DJ, McCowen SM. A multiple plasmid-containing *Escherichia coli*
488 strain: convenient source of size reference plasmid molecules. Plasmid. 1978;1(3):417-20. doi: 10.1016/0147-
489 619x(78)90056-2. PubMed PMID: 372973.
- 490 53. Haider K, Huq MI, Talukder KA, Ahmad QS. Electrophoretotyping of plasmid DNA of different serotypes of
491 *Shigella flexneri* isolated in Bangladesh. Epidemiol Infect. 1989;102(3):421-8. doi: 10.1017/s0950268800030132. PubMed
492 PMID: 2661251; PubMed Central PMCID: PMC2249461.

493

494

495

496

497

498

499

500

501

502 **Table 1. List of PCR primers used in this study.**

Primer	Sequence (5'-3')	Amplicon size (bp)	Annealing Temperature (°C)	Reference
<i>bla</i> -IMP	F- GGA ATA GAG TGG CTT AAT TCT C R- CCA AAC CAC TAC GTT ATC T	188	52	[24]
<i>bla</i> -VIM	F- GAT GGT GTT TGG TCG CAT A R- CGA ATG CGC AGC ACC AG	390	52	[24]
<i>bla</i> -SPM	F- AAA ATC TGG GTA CGC AAA CG R- ACA TTA TCC GCT GGA ACA GG	271	52	[24]
<i>bla</i> -NDM-1	F- CCT ACA ATC TAA CGG CGA CC R- TCG CCG TGT CCA GGT ATA AC	621	56	[48]
ERIC2	AAG TAA GTG ACT GGG GTG AGC G		48	[49]

503
504
505
506
507
508
509
510
511
512
513
514
515
516

517 **Table 2. Collection of samples and culture results**

Sample type	Samples collected from EMCH		Samples collected from GMCH		Total samples	Total <i>P. aeruginosa</i> isolates
	Sample number	Positive for <i>P. aeruginosa</i>	Sample number	Positive for <i>P. aeruginosa</i>		
Urine	72 (62%)	16 (22%)	43 (38%)	7 (16%)	115	23
Urinary Catheter	7 (58%)	4 (57%)	5 (42%)	1 (20%)	12	5
Sec. wound infection	12 (57%)	7 (58%)	9 (43%)	4 (45%)	21	11
Pus	37 (54%)	5 (13%)	32 (46%)	5 (15%)	69	10
Burn wound	8 (80%)	2 (25%)	2 (20%)	0	10	2
Blood	9 (100%)	1 (11%)	0	0	9	1
Tracheal aspirate	2 (100%)	1 (50%)	0	0	2	1
Total	147 (62%)	36 (24%)	91 (38%)	17 (19%)	238	53

518 Here, GMCH = Gonoshasthaya Samaj Vittik Medical College & Hospital; EMCH =
 519 Enam Medical College & Hospital.

520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531

532 **Table 3.** Antibiotic susceptibility and resistance determinants in Imipenem-resistant
533 clinical *P. aeruginosa*

Isolate ID	Specimen (Hospital)	MIC Value (µg/ml)	Phenotypic Detection of MBL Production			Presence of MBL gene				Plasmid (MDa)
			IMP (Zone, mm)	IMP+ EDTA (Zone, mm)	Interpretation	<i>bla</i> -IMP	<i>bla</i> -VIM	<i>bla</i> -SPM	<i>bla</i> -NDM1	
PA01 ^a	Reference	0.5	19	20	Negative	-	-	-	-	-
PU1	Urine (A)	8	0	0	Negative	-	-	-	-	-
PU5	Urine (A)	8	0	14	Negative	-	-	-	-	-
PU6	Urine (A)	8	0	15	Intermediate	-	-	-	-	-
PUS1	Cath. Swb (A)	8	0	15	Intermediate	-	-	-	-	-
PS1	Wound Swb (A)	16	0	16	Intermediate	-	-	-	-	-
PS2	Wound Swb (A)	8	0	15	Intermediate	-	-	-	-	-
PU17	Urine (B)	128	0	22	Positive	-	-	-	+	0.5
PU26	Urine (B)	8	0	20	Positive	-	+	-	-	1.2
PWS12	Wound Swb (B)	32	0	20	Positive	-	+	-	-	-
PWS17	Cath. Swb (B)	128	0	24	Positive	-	-	-	+	0.5, 1.2
PWS18	Cath. Swb (B)	128	0	21	Positive	-	-	-	+	0.5, 1.2
PWS21	Wound Swb (B)	128	0	24	Positive	-	+	-	-	0.2, 1.2
PWS22	Wound Swb (B)	16	0	22	Positive	-	+	-	-	0.2, 1.2
PWS23	Wound Swb (B)	16	0	16	Intermediate	-	+	-	-	-
PWS25	Cath. Swb (B)	8	0	16	Intermediate	-	+	-	-	0.2, 1.2
PWS26	Tracheal Asp (B)	128	0	23	Positive	-	+	-	-	-

534 Here, '+' denotes positive; '-' denotes negative; IMP= Imipenem; A= Gonoshasthaya Samaj Vittik Medical
535 College & Hospital (GMCH); B= Enam Medical College & Hospital (EMCH). Cath. Swb= Catheter Swab;

536 Wound Swb= Secondary Wound Swab; Tracheal Asp= Tracheal Aspirate ^aPAO1: Reference strain in
537 susceptibility testing and β -lactamase assays (NCBI: txid208964).

538

539

540

541


542

543

544


545

546



547 **Figure 1. PCR based detection of MBL variants.** MBL gene sequences were PCR
548 amplified using the variant-specific primers (Table 3). PCR products were
549 electrophoresed through 1% agarose gels, stained with ethidium bromide, and
550 visualized with UV light. The 100 bp DNA ladder indicates the size of PCR products.
551 Lane 2, 7, 12 and 16 represent variant-specific positive controls, and lane 3, 8, 13 and 17
552 represent negative controls. No isolates were positive in *bla-IMP* and *bla-SPM* specific
553 PCR.

554



555

556 **Figure 2. UPGMA cluster analysis of ERIC-PCR results:** A). ERIC-PCR products were
557 electrophoresed on 1% agarose gel, stained with ethidium bromide, and visualized on
558 UV light. Lane 1 represent 100 bp DNA ladder; Lane 8 and 9 represent isolates PWS18
559 and PWS17 respectively showing identical amplification pattern. Similarly, Lane 10 and
560 11 represent isolates PWS22 and PWS21 respectively showing identical amplification.
561 Rest of the lanes represent unique PCR amplification profiles. B). Dendrogram based on
562 UPGMA cluster analysis of ERIC-PCR results; the names of the analyzed strains are
563 mentioned with their phylogenetic groups denominated as Cluster I, II and III.

564




Figure 1. PCR based detection of MBL variants. MBL gene sequences were PCR amplified using the variant-specific primers (Table 3). PCR products were electrophoresed through 1% agarose gels, stained with ethidium bromide, and visualized with UV light. The 100 bp DNA ladder indicates the size of PCR products. Lane 2, 7, 12 and 16 represent variant-specific positive controls, and lane 3, 8, 13 and 17 represent negative controls. No isolates were positive in *bla*-IMP and *bla*-SPM specific PCR.




Figure 2. UPGMA cluster analysis of ERIC-PCR results: A). ERIC-PCR products were electrophoresed on 1% agarose gel, stained with ethidium bromide, and visualized on UV light. Lane 1 represent 100 bp DNA ladder; Lane 8 and 9 represent isolates PWS18 and PWS17 respectively showing identical amplification pattern. Similarly, Lane 10 and 11 represent isolates PWS22 and PWS21 respectively showing identical amplification. Rest of the lanes represent unique PCR amplification profiles. B). Dendrogram based on UPGMA cluster analysis of ERIC-PCR results; the names of the analyzed strains are mentioned with their phylogenetic groups denominated as Cluster I, II and III.

Table 1. List of PCR primers used in this study.

Primer	Sequence (5'-3')	Amplicon size (bp)	Annealing Temperature (°C)	Reference
<i>bla</i> -IMP	F- GGA ATA GAG TGG CTT AAT TCT C	188	52	[24]
	R- CCA AAC CAC TAC GTT ATC T			
<i>bla</i> -VIM	F- GAT GGT GTT TGG TCG CAT A	390	52	[24]
	R- CGA ATG CGC AGC ACC AG			
<i>bla</i> -SPM	F- AAA ATC TGG GTA CGC AAA CG	271	52	[24]
	R- ACA TTA TCC GCT GGA ACA GG			
<i>bla</i> -NDM-1	F- CCT ACA ATC TAA CGG CGA CC	621	56	[48]
	R- TCG CCG TGT CCA GGT ATA AC			
ERIC2	AAG TAA GTG ACT GGG GTG AGC G		48	[49]

Table 2. Collection of samples and culture results

Sample type	Samples collected from EMCH		Samples collected from GMCH		Total samples	Total <i>P. aeruginosa</i> isolates
	Sample number	Positive for <i>P. aeruginosa</i>	Sample number	Positive for <i>P. aeruginosa</i>		
Urine	72 (62%)	16 (22%)	43 (38%)	7 (16%)	115	23
Urinary Catheter	7 (58%)	4 (57%)	5 (42%)	1 (20%)	12	5
Sec. wound infection	12 (57%)	7 (58%)	9 (43%)	4 (45%)	21	11
Pus	37 (54%)	5 (13%)	32 (46%)	5 (15%)	69	10
Burn wound	8 (80%)	2 (25%)	2 (20%)	0	10	2
Blood	9 (100%)	1 (11%)	0	0	9	1
Tracheal aspirate	2 (100%)	1 (50%)	0	0	2	1
Total	147 (62%)	36 (24%)	91 (38%)	17 (19%)	238	53

Here, GMCH = Gonoshasthaya Samaj Vittik Medical College & Hospital; EMCH = Enam Medical College & Hospital.

Table 3. Antibiotic susceptibility and resistance determinants in Imipenem-resistant clinical *P. aeruginosa*

Isolate ID	Specimen (Hospital)	MIC Value (µg/ml)	Phenotypic Detection of MBL Production			Presence of MBL gene				Plasmid (MDa)
			IMP (Zone, mm)	IMP+ EDTA (Zone, mm)	Interpretation	<i>bla</i> -IMP	<i>bla</i> -VIM	<i>bla</i> -SPM	<i>bla</i> -NDM1	
PA01 ^a	Reference	0.5	19	20	Negative	-	-	-	-	-
PU1	Urine (A)	8	0	0	Negative	-	-	-	-	-
PU5	Urine (A)	8	0	14	Negative	-	-	-	-	-
PU6	Urine (A)	8	0	15	Intermediate	-	-	-	-	-
PUS1	Cath. Swb (A)	8	0	15	Intermediate	-	-	-	-	-
PS1	Wound Swb (A)	16	0	16	Intermediate	-	-	-	-	-
PS2	Wound Swb (A)	8	0	15	Intermediate	-	-	-	-	-
PU17	Urine (B)	128	0	22	Positive	-	-	-	+	0.5
PU26	Urine (B)	8	0	20	Positive	-	+	-	-	1.2
PWS12	Wound Swb (B)	32	0	20	Positive	-	+	-	-	-
PWS17	Cath. Swb (B)	128	0	24	Positive	-	-	-	+	0.5, 1.2
PWS18	Cath. Swb (B)	128	0	21	Positive	-	-	-	+	0.5, 1.2
PWS21	Wound Swb (B)	128	0	24	Positive	-	+	-	-	0.2, 1.2
PWS22	Wound Swb (B)	16	0	22	Positive	-	+	-	-	0.2, 1.2
PWS23	Wound Swb (B)	16	0	16	Intermediate	-	+	-	-	-
PWS25	Cath. Swb (B)	8	0	16	Intermediate	-	+	-	-	0.2, 1.2
PWS26	Tracheal Asp (B)	128	0	23	Positive	-	+	-	-	-

Here, '+' denotes positive; '-' denotes negative; IMP= Imipenem; A= Gonoshasthaya Samaj Vittik Medical College & Hospital (GMCH); B= Enam Medical College & Hospital (EMCH). Cath. Swb= Catheter Swab; Wound Swb= Secondary Wound Swab; Tracheal Asp= Tracheal Aspirate

^aPA01: Reference strain in susceptibility testing and β-lactamase assays (NCBI: txid208964).